PTC Therapeutics, Inc. (PTCT) by event type
PTCT moves most on analyst downgrades — a median of +0.83% at 30 minutes across 22 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the PTCT overview →
How PTCT reacts across 6 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 387 of 2,717 | 41 | +0.48% | 56% | +0.30% |
| Analyst downgrades 168 of 2,603 | 22 | +0.83% | 59% | -0.07% |
| Coverage initiations 989 of 2,283 | 23 | +0.05% | 52% | -0.21% |
| Rating reiterations 976 of 3,522 | 122 | +0.08% | 55% | +0.14% |
| Price-target raises 1,115 of 1,790 | 41 | -0.04% | 42% | -0.10% |
| Price-target cuts 887 of 1,527 | 17 | -0.05% | 47% | +1.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one.
That’s how PTCT usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · Price-target raises → · Price-target cuts → · PTCT overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
| ONCOMED PHARMACEUTICALS (OMED) | 677 | -0.20% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.